首页 > 最新文献

European journal of breast health最新文献

英文 中文
Gastrointestinal Tract Metastases of Invasive Lobular Carcinoma of the Breast: An Immunohistochemical Survey Algorithm. 浸润性乳腺小叶癌的胃肠道转移:免疫组织化学调查算法。
Pub Date : 2022-10-01 DOI: 10.4274/ejbh.galenos.2022.2022-1-5
Baha Zengel, Demet Çavdar, Özlem Özdemir, Funda Taşlı, Murat Karataş, Cenk Şimşek, Adam Uslu

Invasive lobular carcinoma (ILC) accounts for almost 15% of all breast carcinomas. The potential of ILC to metastasize to the gastointestinal system is significantly greater than that of invasive ductal carcinoma. Gastric metastasis occurred in the ninth year of the follow-up in a patient who was operated on the right breast due to ILC. The patient was investigated for simultaneous masses in the stomach and colon, and a random mass was found in her right breast.

浸润性小叶癌(ILC)几乎占所有乳腺癌的15%。ILC转移到胃肠道系统的可能性明显大于浸润性导管癌。在随访的第9年发生胃转移的病人在右乳房手术,由于ILC。对患者进行了胃和结肠同时肿块的检查,并在右乳房发现了一个随机肿块。
{"title":"Gastrointestinal Tract Metastases of Invasive Lobular Carcinoma of the Breast: An Immunohistochemical Survey Algorithm.","authors":"Baha Zengel,&nbsp;Demet Çavdar,&nbsp;Özlem Özdemir,&nbsp;Funda Taşlı,&nbsp;Murat Karataş,&nbsp;Cenk Şimşek,&nbsp;Adam Uslu","doi":"10.4274/ejbh.galenos.2022.2022-1-5","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2022.2022-1-5","url":null,"abstract":"<p><p>Invasive lobular carcinoma (ILC) accounts for almost 15% of all breast carcinomas. The potential of ILC to metastasize to the gastointestinal system is significantly greater than that of invasive ductal carcinoma. Gastric metastasis occurred in the ninth year of the follow-up in a patient who was operated on the right breast due to ILC. The patient was investigated for simultaneous masses in the stomach and colon, and a random mass was found in her right breast.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":"18 4","pages":"375-380"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521291/pdf/ejbh-18-375.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33517993","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Salvage Mastectomy Is not the Treatment of Choice for Aggressive Subtypes of Ipsilateral Breast Cancer Recurrence: A Single-Institution Retrospective Study. 挽救性乳房切除术不是同侧乳腺癌复发侵袭性亚型的治疗选择:一项单机构回顾性研究。
Pub Date : 2022-10-01 DOI: 10.4274/ejbh.galenos.2022.2022-5-3
Damiano Gentile, Andrea Sagona, Ruggero Spoto, Davide Franceschini, Stefano Vaccari, Valeriano Vinci, Ersilia Biondi, Lorenzo Scardina, Corrado Tinterri

Objective: Patients with triple-negative (TN) or human epidermal growth factor 2 (HER2)-enriched ipsilateral breast cancer recurrence (IBCR) seem to be excluded from a second breast-conserving surgery (BCS) under the assumption that salvage mastectomy would provide better oncological outcomes. The objective of this study was to describe the clinical features of these patients, to compare the two surgical alternatives (salvage mastectomy versus second BCS) in terms of oncological results, and to identify independent factors influencing prognosis and surgical treatment.

Materials and methods: We retrospectively reviewed all the consecutive patients with histologically confirmed TN or HER2-enriched IBCR. Disease-free survival (DFS), distant disease-free survival (DDFS), overall survival (OS), and breast cancer-specific survival (BCSS) were analyzed and compared between the two groups.

Results: Eighty-five patients were affected by TN or HER2-enriched IBCR. The majority of patients (72.9%) were treated with salvage mastectomy. There was no significant difference in terms of DFS between patients receiving a second BCS or mastectomy (p = 0.596). However, patients undergoing a second BCS had significantly better DDFS, OS and BCSS compared to mastectomy (p = 0.009; p = 0.002; p = 0.001, respectively). Tumor dimension <16 mm was found to significantly increase the probability of receiving a second BCS and positively affects recurrence and survival outcomes. Salvage mastectomy represents an independent poor prognostic factor for OS and BCSS.

Conclusion: Salvage mastectomy is not always necessary and it does not seem to increase survival compared to a second BCS. In patients with small aggressive subtypes of IBCR, a second conservative approach can still be evaluated and offered, presenting acceptable loco-regional control and survival.

目的:三阴性(TN)或人表皮生长因子2 (HER2)富集的同侧乳腺癌复发(IBCR)患者似乎被排除在第二次保乳手术(BCS)之外,假设保留性乳房切除术可以提供更好的肿瘤预后。本研究的目的是描述这些患者的临床特征,比较两种手术选择(保留性乳房切除术与二次BCS)的肿瘤结果,并确定影响预后和手术治疗的独立因素。材料和方法:我们回顾性回顾了所有连续的组织学证实的TN或her2富集IBCR患者。分析比较两组患者的无病生存期(DFS)、远端无病生存期(DDFS)、总生存期(OS)和乳腺癌特异性生存期(BCSS)。结果:85例患者有TN或her2富集的IBCR。大多数患者(72.9%)行保留性乳房切除术。在接受第二次BCS或乳房切除术的患者之间,DFS没有显著差异(p = 0.596)。然而,与乳房切除术相比,接受第二次BCS的患者具有更好的DDFS, OS和BCSS (p = 0.009;P = 0.002;P = 0.001)。结论:补救性乳房切除术并不总是必要的,与第二次BCS相比,它似乎并不能提高生存率。对于小侵袭性IBCR亚型患者,仍然可以评估和提供第二种保守方法,表现出可接受的局部区域控制和生存率。
{"title":"Salvage Mastectomy Is not the Treatment of Choice for Aggressive Subtypes of Ipsilateral Breast Cancer Recurrence: A Single-Institution Retrospective Study.","authors":"Damiano Gentile,&nbsp;Andrea Sagona,&nbsp;Ruggero Spoto,&nbsp;Davide Franceschini,&nbsp;Stefano Vaccari,&nbsp;Valeriano Vinci,&nbsp;Ersilia Biondi,&nbsp;Lorenzo Scardina,&nbsp;Corrado Tinterri","doi":"10.4274/ejbh.galenos.2022.2022-5-3","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2022.2022-5-3","url":null,"abstract":"<p><strong>Objective: </strong>Patients with triple-negative (TN) or human epidermal growth factor 2 (HER2)-enriched ipsilateral breast cancer recurrence (IBCR) seem to be excluded from a second breast-conserving surgery (BCS) under the assumption that salvage mastectomy would provide better oncological outcomes. The objective of this study was to describe the clinical features of these patients, to compare the two surgical alternatives (salvage mastectomy <i>versus</i> second BCS) in terms of oncological results, and to identify independent factors influencing prognosis and surgical treatment.</p><p><strong>Materials and methods: </strong>We retrospectively reviewed all the consecutive patients with histologically confirmed TN or HER2-enriched IBCR. Disease-free survival (DFS), distant disease-free survival (DDFS), overall survival (OS), and breast cancer-specific survival (BCSS) were analyzed and compared between the two groups.</p><p><strong>Results: </strong>Eighty-five patients were affected by TN or HER2-enriched IBCR. The majority of patients (72.9%) were treated with salvage mastectomy. There was no significant difference in terms of DFS between patients receiving a second BCS or mastectomy (<i>p</i> = 0.596). However, patients undergoing a second BCS had significantly better DDFS, OS and BCSS compared to mastectomy (<i>p</i> = 0.009; <i>p</i> = 0.002; <i>p</i> = 0.001, respectively). Tumor dimension <16 mm was found to significantly increase the probability of receiving a second BCS and positively affects recurrence and survival outcomes. Salvage mastectomy represents an independent poor prognostic factor for OS and BCSS.</p><p><strong>Conclusion: </strong>Salvage mastectomy is not always necessary and it does not seem to increase survival compared to a second BCS. In patients with small aggressive subtypes of IBCR, a second conservative approach can still be evaluated and offered, presenting acceptable loco-regional control and survival.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":"18 4","pages":"315-322"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521294/pdf/ejbh-18-315.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33517576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Health-Related Quality of Life in Women With Breast Cancer Undergoing Treatment With Hormonal Therapy - A Review Study. 接受激素治疗的乳腺癌患者与健康相关的生活质量研究综述
Pub Date : 2022-10-01 DOI: 10.4274/ejbh.galenos.2022.2022-5-8
Lamya Alnaim

This review aimed to analyze the significance and impact of health-related quality of life (QoL) in women with breast cancer undergoing treatment with hormonal therapy. This study developed a comprehensive, structured, systematic search strategy to identify literature related to health and QoL in breast cancer patients undergoing treatment with hormonal therapy. The search was conducted for published literature indexed in PubMed (Medline), Cancer Lit, CINAHL, Google Scholar, and Web of Science between 2010 and 2020. Patients associated with the study of QoL reported some difficulties in terms of depression, anxiety, chronic fatigue, sleep problems, pain, sexual dysfunction and sleep disorders. Endocrine-related symptoms did not fluctuate between interventions and remained unchanged in all groups. The evaluation of FACT-G scores (physical well-being subscale) showed statistically significant differences among participants receiving anastrozole versus tamoxifen and exemestane. It can be concluded that the QoL of postmenopausal women with breast cancer is affected by the long-term use of adjuvant endocrine therapy, with difference reported associated with the different therapies. However, further efforts are required to improve QoL instruments and the quantitative evaluation of QoL data for patients receiving adjuvant ET.

本综述旨在分析接受激素治疗的乳腺癌患者健康相关生活质量(QoL)的意义和影响。本研究开发了一个全面的、结构化的、系统的搜索策略,以确定与接受激素治疗的乳腺癌患者的健康和生活质量相关的文献。该搜索是针对2010年至2020年间在PubMed (Medline)、Cancer Lit、CINAHL、Google Scholar和Web of Science上索引的已发表文献进行的。与生活质量研究相关的患者报告了一些困难,包括抑郁、焦虑、慢性疲劳、睡眠问题、疼痛、性功能障碍和睡眠障碍。内分泌相关症状在干预措施之间没有波动,并且在所有组中保持不变。FACT-G评分(身体健康量表)的评估显示,接受阿那曲唑与他莫昔芬和依西美坦治疗的参与者之间存在统计学上的显著差异。由此可见,长期使用辅助内分泌治疗对绝经后乳腺癌患者的生活质量有影响,不同的治疗方法有差异。然而,对于接受辅助ET治疗的患者,需要进一步努力改进生活质量仪器和生活质量数据的定量评估。
{"title":"Health-Related Quality of Life in Women With Breast Cancer Undergoing Treatment With Hormonal Therapy - A Review Study.","authors":"Lamya Alnaim","doi":"10.4274/ejbh.galenos.2022.2022-5-8","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2022.2022-5-8","url":null,"abstract":"<p><p>This review aimed to analyze the significance and impact of health-related quality of life (QoL) in women with breast cancer undergoing treatment with hormonal therapy. This study developed a comprehensive, structured, systematic search strategy to identify literature related to health and QoL in breast cancer patients undergoing treatment with hormonal therapy. The search was conducted for published literature indexed in PubMed (Medline), Cancer Lit, CINAHL, Google Scholar, and Web of Science between 2010 and 2020. Patients associated with the study of QoL reported some difficulties in terms of depression, anxiety, chronic fatigue, sleep problems, pain, sexual dysfunction and sleep disorders. Endocrine-related symptoms did not fluctuate between interventions and remained unchanged in all groups. The evaluation of FACT-G scores (physical well-being subscale) showed statistically significant differences among participants receiving anastrozole versus tamoxifen and exemestane. It can be concluded that the QoL of postmenopausal women with breast cancer is affected by the long-term use of adjuvant endocrine therapy, with difference reported associated with the different therapies. However, further efforts are required to improve QoL instruments and the quantitative evaluation of QoL data for patients receiving adjuvant ET.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":"18 4","pages":"292-298"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521283/pdf/ejbh-18-292.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33517574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Evaluation of Arab Cultural Barriers That Influence Muslim Arab Iraqi Women's Breast Cancer Screening Behavior. 影响穆斯林阿拉伯伊拉克妇女乳腺癌筛查行为的阿拉伯文化障碍评价
Pub Date : 2022-10-01 DOI: 10.4274/ejbh.galenos.2022.2022-5-6
Shadan Shukur Azeez, Işıl Işık Andsoy

Objective: Little is known about Iraqi women's practice towards breast cancer screening (BCS), breast self-examination (BSE), clinical breast examination (CBE) and mammography, and the influence of Arab culture. The aim of this study was to assess women's behavior towards BCS, and to explain the influence of specific Arab culture barriers.

Materials and methods: This descriptive study was carried out with 1,066 women. Three structured questionnaires were used in the data collection. Descriptive statistics and multivariable logistic regression were used for data evaluation.

Results: Many Iraqi women did not practice regular BSE, CBE, and mammography. The most common reason was "not having a breast complaint". Specific Arab cultural barriers such as exposure [odds ratio (OR) = 0.545; 95% confidence interval (CI) = 0.440 to 0.674; p<0.001], environment (OR = 0.571; 95% CI = 0.464 to 0.703; p<0.001) and uneasiness barriers (OR = 0.736; 95% CI = 0.557 to 0.974; p=0.032) were predictors for BSE while exposure (OR = 0.553; 95% CI = 0.447 to 0.684; p<0.001), and environment barriers (OR = 0.585; 95% CI = 0.474 to 0.772; p<0.001) was predictor for CBE. Additionally, exposure (OR = 0.324; 95% CI = 0.251 to 0.419; p<0.001), environment (OR = 0.636; 95% CI = 0.500 to 0.809; p<0.001), and uneasiness barriers (OR = 0.644; 95% CI = 0.464 to 0.893; p = 0.008) were predictors for mammography screening of Iraqi women.

Conclusion: Arab specific cultural barriers may be one of the key obstacles to BSC uptake in Iraq. Health education, including cultural education, may have the potential to increase BCS awareness and down-staging of the disease at presentation.

目的:了解伊拉克妇女乳腺癌筛查(BCS)、乳房自检(BSE)、临床乳房检查(CBE)和乳房x光检查的实践情况,以及阿拉伯文化的影响。本研究的目的是评估女性对BCS的行为,并解释特定阿拉伯文化障碍的影响。材料和方法:本研究对1066名女性进行了描述性研究。数据收集采用三份结构化问卷。采用描述性统计和多变量logistic回归进行资料评价。结果:许多伊拉克妇女没有进行常规的疯牛病、CBE和乳房x光检查。最常见的原因是“没有乳房不适”。特定的阿拉伯文化障碍,如暴露[优势比(OR) = 0.545;95%置信区间(CI) = 0.440 ~ 0.674;ppppppp = 0.008)是伊拉克妇女乳房x光检查的预测因子。结论:阿拉伯特有的文化障碍可能是伊拉克采用平衡记分卡的主要障碍之一。健康教育,包括文化教育,可能有潜力提高对BCS的认识,并在发病时降低疾病的分期。
{"title":"Evaluation of Arab Cultural Barriers That Influence Muslim Arab Iraqi Women's Breast Cancer Screening Behavior.","authors":"Shadan Shukur Azeez,&nbsp;Işıl Işık Andsoy","doi":"10.4274/ejbh.galenos.2022.2022-5-6","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2022.2022-5-6","url":null,"abstract":"<p><strong>Objective: </strong>Little is known about Iraqi women's practice towards breast cancer screening (BCS), breast self-examination (BSE), clinical breast examination (CBE) and mammography, and the influence of Arab culture. The aim of this study was to assess women's behavior towards BCS, and to explain the influence of specific Arab culture barriers.</p><p><strong>Materials and methods: </strong>This descriptive study was carried out with 1,066 women. Three structured questionnaires were used in the data collection. Descriptive statistics and multivariable logistic regression were used for data evaluation.</p><p><strong>Results: </strong>Many Iraqi women did not practice regular BSE, CBE, and mammography. The most common reason was \"not having a breast complaint\". Specific Arab cultural barriers such as exposure [odds ratio (OR) = 0.545; 95% confidence interval (CI) = 0.440 to 0.674; <i>p</i><0.001], environment (OR = 0.571; 95% CI = 0.464 to 0.703; <i>p</i><0.001) and uneasiness barriers (OR = 0.736; 95% CI = 0.557 to 0.974; p=0.032) were predictors for BSE while exposure (OR = 0.553; 95% CI = 0.447 to 0.684; <i>p</i><0.001), and environment barriers (OR = 0.585; 95% CI = 0.474 to 0.772; <i>p</i><0.001) was predictor for CBE. Additionally, exposure (OR = 0.324; 95% CI = 0.251 to 0.419; <i>p</i><0.001), environment (OR = 0.636; 95% CI = 0.500 to 0.809; <i>p</i><0.001), and uneasiness barriers (OR = 0.644; 95% CI = 0.464 to 0.893; <i>p</i> = 0.008) were predictors for mammography screening of Iraqi women.</p><p><strong>Conclusion: </strong>Arab specific cultural barriers may be one of the key obstacles to BSC uptake in Iraq. Health education, including cultural education, may have the potential to increase BCS awareness and down-staging of the disease at presentation.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":"18 4","pages":"329-335"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521288/pdf/ejbh-18-329.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33517575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Co-Existence of Two Rare Entities in the Male Breast: Intraductal Papilloma and Angiolipoma. 男性乳腺导管内乳头状瘤和血管脂肪瘤两种罕见肿瘤的共存。
Pub Date : 2022-10-01 DOI: 10.4274/ejbh.galenos.2022.2022-1-7
Murat Baykara, Hilal Balta, Erhan Cahit Özcan

Intraductal papilloma and angiolipoma lesions are very rare in male breasts and gynecomastia is the most common male breast pathology. A 52-year-old healthy Caucasian male patient with right nipple pain for one month and two subareolar and periareolar masses had no other abnormal clinical or laboratory findings. After ultrasound examination, pull-through excision was made with a circumareolar incision in both lesions and the samples were sent for pathological examination. Histopathological examination revealed intraductal papilloma and angiolipoma on the basis of gynecomastia. This case is unique because both lesions are extremely rare and this is the first report of concurrent occurrence in a male breast.

导管内乳头状瘤和血管脂肪瘤病变在男性乳房中非常罕见,而男性乳房发育是最常见的男性乳房病理。52岁健康白人男性,右乳头疼痛1个月,乳晕下及乳晕周围肿物2个,无其他异常临床及实验室表现。超声检查后,在两个病变处做环晕切口,并将标本送病理检查。组织病理学检查显示导管内乳头状瘤和血管脂肪瘤的基础上,男性乳房。这个病例是独特的,因为这两种病变都是非常罕见的,这是第一个同时发生在男性乳房的报告。
{"title":"Co-Existence of Two Rare Entities in the Male Breast: Intraductal Papilloma and Angiolipoma.","authors":"Murat Baykara,&nbsp;Hilal Balta,&nbsp;Erhan Cahit Özcan","doi":"10.4274/ejbh.galenos.2022.2022-1-7","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2022.2022-1-7","url":null,"abstract":"<p><p>Intraductal papilloma and angiolipoma lesions are very rare in male breasts and gynecomastia is the most common male breast pathology. A 52-year-old healthy Caucasian male patient with right nipple pain for one month and two subareolar and periareolar masses had no other abnormal clinical or laboratory findings. After ultrasound examination, pull-through excision was made with a circumareolar incision in both lesions and the samples were sent for pathological examination. Histopathological examination revealed intraductal papilloma and angiolipoma on the basis of gynecomastia. This case is unique because both lesions are extremely rare and this is the first report of concurrent occurrence in a male breast.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":"18 4","pages":"371-374"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521292/pdf/ejbh-18-371.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33516165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male Breast Cancer Patients. BRCA突变型和野生型男性乳腺癌患者临床、病理和预后特征的比较
Pub Date : 2022-10-01 DOI: 10.4274/ejbh.galenos.2022.2022-5-2
İzzet Doğan, Esra Aydın, Hülya Yazıcı, Pınar Saip

Objective: Published studies on male breast cancer (MBC) and BRCA mutations are scarce and usually include, a small number of patients. The clinicopathological characteristics of BRCA mutant and wild-type MBC patients were compared in more than forty patients in this study.

Materials and methods: A retrospective review of MBC patients' clinical and histopathological data was conducted. To compare the patients' characteristics, chi-square test and Fisher's Exact test were utilized. Kaplan-Meier analysis was used to examine the survival analysis.

Results: In total 43 cases were reviewed. The average duration of follow-up was 35.8 months. BRCA mutations were found in 11 (25.6%) of the patients. BRCA1 mutations were found in four patients (9.3%), BRCA2 mutations in six patients (14%), and BRCA1 and BRCA2 mutations in one patient (2.3%). The median age at diagnosis was 58 years old, and there was no statistically significant difference between groups (p = 0.7). Tumor location (p = 0.3), human epidermal growth factor receptor 2 overexpression (p = 0.5), estrogen receptor status (p = 0.05), progesterone receptor status (p = 0.6), tumor stage (p = 0.9), lymph node positivity (p = 0.5), tumor histology (p = 0.06), and recurrence status (p = 0.6) were similar between BRCA-wild type and -mutated patients. Overall survival averaged 115.6 months (range: 76.0-155.3), with no statistically significant differences between groups (p = 0.6).

Conclusion: This study investigated clinical and pathological characteristics and prognoses of BRCA wild and mutant-type MBC and these were similar in all groups studied.

目的:关于男性乳腺癌(MBC)和BRCA突变的已发表的研究很少,通常只包括少数患者。本研究比较了40多例BRCA突变型和野生型MBC患者的临床病理特征。材料和方法:回顾性分析MBC患者的临床和组织病理学资料。比较两组患者的特征,采用卡方检验和Fisher’s Exact检验。采用Kaplan-Meier分析对生存分析进行检验。结果:共回顾43例。平均随访时间为35.8个月。11例(25.6%)患者发现BRCA突变。4例患者(9.3%)发现BRCA1突变,6例患者(14%)发现BRCA2突变,1例患者(2.3%)发现BRCA1和BRCA2突变。诊断时中位年龄为58岁,组间差异无统计学意义(p = 0.7)。brca野生型和突变型患者的肿瘤位置(p = 0.3)、人表皮生长因子受体2过表达(p = 0.5)、雌激素受体状态(p = 0.05)、孕激素受体状态(p = 0.6)、肿瘤分期(p = 0.9)、淋巴结阳性(p = 0.5)、肿瘤组织学(p = 0.06)、复发状态(p = 0.6)相似。总生存期平均为115.6个月(76.0 ~ 155.3个月),组间差异无统计学意义(p = 0.6)。结论:本研究调查了BRCA野生型和突变型MBC的临床、病理特征和预后,所有研究组均相似。
{"title":"Comparison of Clinical, Pathological, and Prognostic Features in <i>BRCA</i> Mutant and Wild-Type Male Breast Cancer Patients.","authors":"İzzet Doğan,&nbsp;Esra Aydın,&nbsp;Hülya Yazıcı,&nbsp;Pınar Saip","doi":"10.4274/ejbh.galenos.2022.2022-5-2","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2022.2022-5-2","url":null,"abstract":"<p><strong>Objective: </strong>Published studies on male breast cancer (MBC) and <i>BRCA</i> mutations are scarce and usually include, a small number of patients. The clinicopathological characteristics of <i>BRCA</i> mutant and wild-type MBC patients were compared in more than forty patients in this study.</p><p><strong>Materials and methods: </strong>A retrospective review of MBC patients' clinical and histopathological data was conducted. To compare the patients' characteristics, chi-square test and Fisher's Exact test were utilized. Kaplan-Meier analysis was used to examine the survival analysis.</p><p><strong>Results: </strong>In total 43 cases were reviewed. The average duration of follow-up was 35.8 months. <i>BRCA</i> mutations were found in 11 (25.6%) of the patients. <i>BRCA1</i> mutations were found in four patients (9.3%), <i>BRCA2</i> mutations in six patients (14%), and <i>BRCA1</i> and <i>BRCA2</i> mutations in one patient (2.3%). The median age at diagnosis was 58 years old, and there was no statistically significant difference between groups (<i>p</i> = 0.7). Tumor location (<i>p</i> = 0.3), human epidermal growth factor receptor 2 overexpression (<i>p</i> = 0.5), estrogen receptor status (<i>p</i> = 0.05), progesterone receptor status (<i>p</i> = 0.6), tumor stage (<i>p</i> = 0.9), lymph node positivity (<i>p</i> = 0.5), tumor histology (<i>p</i> = 0.06), and recurrence status (<i>p</i> = 0.6) were similar between <i>BRCA</i>-wild type and -mutated patients. Overall survival averaged 115.6 months (range: 76.0-155.3), with no statistically significant differences between groups (<i>p</i> = 0.6).</p><p><strong>Conclusion: </strong>This study investigated clinical and pathological characteristics and prognoses of <i>BRCA</i> wild and mutant-type MBC and these were similar in all groups studied.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":"18 4","pages":"323-328"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521287/pdf/ejbh-18-323.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33516164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes. 纯黏液性乳腺癌具有良好的肿瘤生物学和临床结果。
Pub Date : 2022-10-01 DOI: 10.4274/ejbh.galenos.2022.2022-8-1
Selman Emiroglu, Mustafa Tukenmez, Seyma Karakus, Hasan Karanlik, Semen Onder, Vahit Ozmen, Neslihan Cabioglu, Enver Ozkurt, Ravza Yilmaz, Mahmut Muslumanoglu

Objective: A few studies suggest that mucinous breast carcinoma (MBC) is a rare breast carcinoma with good prognostic features. Therefore, the aim of this study was to evaluate biological features and clinicopathological characteristics of pure mucinous breast carcinoma (PMBC) to determine clinical outcome in PMBC.

Materials and methods: The data of 87 patients diagnosed with PMBC between November 2004 and February 2022 were retrospectively analyzed in terms of clinicopathological and demographic characteristics, management, and outcome.

Results: The majority of the patients in this study were female, with a median (range) age of 63 (28-90) years. Out of 87 patients, 60 had breast conserving surgery, 27 had a mastectomy, 58 had sentinel lymph node biopsy (SLNB), and 24 had axillary dissection due to a positive SLNB or clinical axilla. Due to age and comorbidities, five patients were not suitable for axillary surgery. The median largest tumor diameter was 23 (5-100) mm. Only 23 patients (26.4%) received adjuvant chemotherapy, whereas almost all patients received hormone therapy. The median duration of follow-up was 53 (6-207) months. There was no local or systemic recurrence in any of the patients. Only 10 patients (11.5%) died from non-cancer causes during the follow-up and treatment period. In this study, tumor diameter was significantly higher in grade II/III tumors (p = 0.039) and in patients under the age of 50 (p = 0.027). Furthermore, lymph node metastasis was statistically significantly more likely in patients under the age of 50 (60% versus 40%, p = 0.013). Patients who had not received chemotherapy or radiotherapy tended to be older than 50 years (p = 0.002).

Conclusion: In this study, the majority of patients were in the luminal subgroups with excellent prognosis and low incidences of lymph node metastasis. As a result, PMBC has favorable tumor biology. We believe that minimal axillary surgery would be the most appropriate approach during patient treatment, due to the low rate of lymph node involvement and favorable prognosis in PMBC patients.

目的:一些研究表明,粘液性乳腺癌(MBC)是一种罕见的预后良好的乳腺癌。因此,本研究的目的是评估纯黏液性乳腺癌(PMBC)的生物学特征和临床病理特征,以确定PMBC的临床预后。材料和方法:回顾性分析2004年11月至2022年2月期间确诊为PMBC的87例患者的临床病理和人口学特征、治疗和结局。结果:本研究中大多数患者为女性,年龄中位数(范围)为63岁(28-90岁)。87例患者中,60例行保乳手术,27例行乳房切除术,58例行前哨淋巴结活检(SLNB), 24例因SLNB或临床腋窝阳性而行腋窝清扫。由于年龄和合并症,5例患者不适合腋窝手术。肿瘤直径中位数最大为23 (5-100)mm。只有23例(26.4%)患者接受了辅助化疗,而几乎所有患者都接受了激素治疗。中位随访时间为53(6-207)个月。所有患者均无局部或全身复发。在随访和治疗期间,只有10例患者(11.5%)死于非癌症原因。在本研究中,II/III级肿瘤(p = 0.039)和50岁以下患者的肿瘤直径明显更高(p = 0.027)。此外,50岁以下的患者更有可能发生淋巴结转移(60%比40%,p = 0.013)。未接受化疗或放疗的患者年龄倾向于50岁以上(p = 0.002)。结论:本组患者以管腔亚组居多,预后良好,淋巴结转移发生率低。因此,PMBC具有良好的肿瘤生物学特性。由于PMBC患者淋巴结受累率低且预后良好,我们认为最小的腋窝手术将是患者治疗过程中最合适的方法。
{"title":"Pure Mucinous Breast Carcinoma With a Favorable Tumor Biology and Clinical Outcomes.","authors":"Selman Emiroglu,&nbsp;Mustafa Tukenmez,&nbsp;Seyma Karakus,&nbsp;Hasan Karanlik,&nbsp;Semen Onder,&nbsp;Vahit Ozmen,&nbsp;Neslihan Cabioglu,&nbsp;Enver Ozkurt,&nbsp;Ravza Yilmaz,&nbsp;Mahmut Muslumanoglu","doi":"10.4274/ejbh.galenos.2022.2022-8-1","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2022.2022-8-1","url":null,"abstract":"<p><strong>Objective: </strong>A few studies suggest that mucinous breast carcinoma (MBC) is a rare breast carcinoma with good prognostic features. Therefore, the aim of this study was to evaluate biological features and clinicopathological characteristics of pure mucinous breast carcinoma (PMBC) to determine clinical outcome in PMBC.</p><p><strong>Materials and methods: </strong>The data of 87 patients diagnosed with PMBC between November 2004 and February 2022 were retrospectively analyzed in terms of clinicopathological and demographic characteristics, management, and outcome.</p><p><strong>Results: </strong>The majority of the patients in this study were female, with a median (range) age of 63 (28-90) years. Out of 87 patients, 60 had breast conserving surgery, 27 had a mastectomy, 58 had sentinel lymph node biopsy (SLNB), and 24 had axillary dissection due to a positive SLNB or clinical axilla. Due to age and comorbidities, five patients were not suitable for axillary surgery. The median largest tumor diameter was 23 (5-100) mm. Only 23 patients (26.4%) received adjuvant chemotherapy, whereas almost all patients received hormone therapy. The median duration of follow-up was 53 (6-207) months. There was no local or systemic recurrence in any of the patients. Only 10 patients (11.5%) died from non-cancer causes during the follow-up and treatment period. In this study, tumor diameter was significantly higher in grade II/III tumors (<i>p</i> = 0.039) and in patients under the age of 50 (<i>p</i> = 0.027). Furthermore, lymph node metastasis was statistically significantly more likely in patients under the age of 50 (60% versus 40%, <i>p</i> = 0.013). Patients who had not received chemotherapy or radiotherapy tended to be older than 50 years (<i>p</i> = 0.002).</p><p><strong>Conclusion: </strong>In this study, the majority of patients were in the luminal subgroups with excellent prognosis and low incidences of lymph node metastasis. As a result, PMBC has favorable tumor biology. We believe that minimal axillary surgery would be the most appropriate approach during patient treatment, due to the low rate of lymph node involvement and favorable prognosis in PMBC patients.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":"18 4","pages":"353-359"},"PeriodicalIF":0.0,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521282/pdf/ejbh-18-353.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33517570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Influence of Screening Mammography Cessation and Resumption on Breast Cancer Presentation and Treatment: A Multi-Hospital Health System Experience During the Early COVID-19 Pandemic. 停止和恢复筛查乳房x光检查对乳腺癌表现和治疗的影响:早期COVID-19大流行期间多医院卫生系统的经验
Pub Date : 2022-09-28 eCollection Date: 2022-10-01 DOI: 10.4274/ejbh.galenos.2022.2022-4-4
Holly Mason, Ann-Kristin Friedrich, Shiva Niakan, Danielle Jacobbe, Jesse Casaubon, Aixa Pérez Coulter

Objective: To assess the impact of the coronavirus disease-2019 (COVID-19) pandemic screening restrictions on the diagnosis and treatment of breast cancer in a single health system.

Materials and methods: We performed a retrospective, cohort investigation of breast cancer patients at a multi-institution health system from March 1, 2019 to December 31, 2020 with two time periods related to the pandemic: "Early phase" (March 18 - June 7) reflecting the time of the screening mammography moratorium and "Late phase" (June 8 - December 31) to reflect the time once screening mammography resumed. 2020 was compared to 2019 to exclude potential differences from temporal or seasonal changes. Variables included demographics, COVID related-deferral, cancer specific data, method of detection, type of treatment recommended and received.

Results: Fewer patients presented with a breast cancer diagnosis during Early phase 2020 when compared to any other time period. Numbers increased significantly in Late phase 2020; total numbers of patients seen in 2020 approached but did not completely reach that of 2019. When compared to other time periods, patients who presented during the moratorium on screening were younger, more likely to be black, had a higher Body Mass Index, and were more likely to have a human epidermal growth factor receptor 2 positive tumor. There was a slight increase in size of presenting tumor and node positivity, although no differences in breast or axillary surgical management were identified.

Conclusion: Despite an increase in tumor size and positive nodal status seen during the screening moratorium, surgical treatment was not negatively impacted.

目的:评估单一卫生系统冠状病毒病-2019 (COVID-19)大流行筛查限制对乳腺癌诊疗的影响。材料和方法:我们对2019年3月1日至2020年12月31日在一个多机构卫生系统中的乳腺癌患者进行了回顾性队列调查,其中有两个与大流行相关的时间段:“早期”(3月18日至6月7日),反映暂停筛查乳房x光检查的时间;“晚期”(6月8日至12月31日),反映恢复筛查乳房x光检查的时间。将2020年与2019年进行比较,以排除时间或季节变化带来的潜在差异。变量包括人口统计、与COVID相关的延迟、癌症特定数据、检测方法、推荐和接受的治疗类型。结果:与其他任何时期相比,在2020年早期诊断出乳腺癌的患者较少。在2020年后期,数量显著增加;2020年的患者总数接近但未完全达到2019年的水平。与其他时间段相比,在暂停筛查期间就诊的患者更年轻,更有可能是黑人,身体质量指数更高,更有可能患有人类表皮生长因子受体2阳性肿瘤。虽然在乳房或腋窝手术治疗方面没有发现差异,但呈现肿瘤和淋巴结阳性的大小略有增加。结论:尽管在筛查暂停期间肿瘤大小和阳性淋巴结状态增加,但手术治疗并未受到负面影响。
{"title":"The Influence of Screening Mammography Cessation and Resumption on Breast Cancer Presentation and Treatment: A Multi-Hospital Health System Experience During the Early COVID-19 Pandemic.","authors":"Holly Mason,&nbsp;Ann-Kristin Friedrich,&nbsp;Shiva Niakan,&nbsp;Danielle Jacobbe,&nbsp;Jesse Casaubon,&nbsp;Aixa Pérez Coulter","doi":"10.4274/ejbh.galenos.2022.2022-4-4","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2022.2022-4-4","url":null,"abstract":"<p><strong>Objective: </strong>To assess the impact of the coronavirus disease-2019 (COVID-19) pandemic screening restrictions on the diagnosis and treatment of breast cancer in a single health system.</p><p><strong>Materials and methods: </strong>We performed a retrospective, cohort investigation of breast cancer patients at a multi-institution health system from March 1, 2019 to December 31, 2020 with two time periods related to the pandemic: \"Early phase\" (March 18 - June 7) reflecting the time of the screening mammography moratorium and \"Late phase\" (June 8 - December 31) to reflect the time once screening mammography resumed. 2020 was compared to 2019 to exclude potential differences from temporal or seasonal changes. Variables included demographics, COVID related-deferral, cancer specific data, method of detection, type of treatment recommended and received.</p><p><strong>Results: </strong>Fewer patients presented with a breast cancer diagnosis during Early phase 2020 when compared to any other time period. Numbers increased significantly in Late phase 2020; total numbers of patients seen in 2020 approached but did not completely reach that of 2019. When compared to other time periods, patients who presented during the moratorium on screening were younger, more likely to be black, had a higher Body Mass Index, and were more likely to have a human epidermal growth factor receptor 2 positive tumor. There was a slight increase in size of presenting tumor and node positivity, although no differences in breast or axillary surgical management were identified.</p><p><strong>Conclusion: </strong>Despite an increase in tumor size and positive nodal status seen during the screening moratorium, surgical treatment was not negatively impacted.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":"18 4","pages":"306-314"},"PeriodicalIF":0.0,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9521286/pdf/ejbh-18-306.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33517573","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Clinical Significance of Radiologically Detected Small Indeterminate Extra-Mammary Lesions in Breast Cancer Patients. 乳腺癌患者放射学检测到的乳腺外小不确定病变的临床意义。
Pub Date : 2022-07-01 DOI: 10.4274/ejbh.galenos.2022.2022-1-2
Rachel Yanlin Chen, Rui Ying Goh, Hoi Ting Leung, Stephanie Cheng, Veronique Kiak Mien Tan, Clement Luck Khng Chia, Jerry Tiong Thye Goo, Marc Weijie Ong

Objective: Patients with breast cancer who have indeterminate extra-mammary lesions, for example in lung, liver or bone, without other metastatic lesions pose a clinical dilemma regarding subsequent management. This study aimed to investigate the prevalence, characteristics and outcomes of such lesions detected on initial staging imaging, and address the clinical significance of these incidental findings.

Materials and methods: Medical records of patients with newly diagnosed breast cancer who underwent computed tomography scans and bone scintigraphy between January 1, 2015 and June 30, 2021 were reviewed. Patients with indeterminate extra-mammary lesions on imaging were included. Patients with obvious metastatic disease were excluded. Lesion characteristics, breast cancer staging, duration of follow-up and natural history of disease progression were analysed.

Results: The study included 52 patients with indeterminate lesions on pre-operative imaging. The median follow-up duration was 14 (range: 6-41) months. The most common site of occurrence of indeterminate lesions was the lung (60.9%) followed by the liver (26.1%). Forty-six had lesions that remained stable (88.5%), while six (11.5%) had progression to metastatic disease. Out of these six, only two (3.8%) developed metastasis in the same site as the original indeterminate lesion, whereas the remaining four developed metastases in other sites.

Conclusion: Patients with breast malignancy found to have indeterminate extra-mammary lesions without obvious distant metastasis on initial staging scans are associated with a small risk of subsequently developing metastatic disease. Although most of these lesions remain quiescent, surveillance imaging is recommended because a small but significant proportion of patients with such lesions eventually harbour actual metastatic disease.

目的:乳腺癌患者如果有不确定的乳腺外病变,如肺部、肝脏或骨骼病变,但没有其他转移性病变,会给后续治疗带来临床难题。本研究旨在调查在初步分期成像中发现的此类病变的发生率、特征和结果,并探讨这些偶然发现的临床意义:研究人员回顾了2015年1月1日至2021年6月30日期间接受计算机断层扫描和骨闪烁扫描的新诊断乳腺癌患者的病历。影像学检查发现乳腺外病变的患者包括在内。不包括有明显转移性疾病的患者。对病灶特征、乳腺癌分期、随访时间和疾病进展的自然史进行了分析:研究共纳入52例术前影像学检查病灶不确定的患者。中位随访时间为 14 个月(6-41 个月)。发生不确定病变的最常见部位是肺(60.9%),其次是肝(26.1%)。46例病变保持稳定(88.5%),6例(11.5%)发展为转移性疾病。在这6人中,只有2人(3.8%)在原发不确定病灶的同一部位发生转移,而其余4人则在其他部位发生转移:结论:乳腺恶性肿瘤患者在最初的分期扫描中被发现有乳腺外不确定病变,但没有明显的远处转移,其随后发生转移性疾病的风险较小。尽管这些病灶大多处于静止状态,但仍建议进行监测成像,因为在有此类病灶的患者中,有一小部分最终会出现真正的转移性疾病。
{"title":"Clinical Significance of Radiologically Detected Small Indeterminate Extra-Mammary Lesions in Breast Cancer Patients.","authors":"Rachel Yanlin Chen, Rui Ying Goh, Hoi Ting Leung, Stephanie Cheng, Veronique Kiak Mien Tan, Clement Luck Khng Chia, Jerry Tiong Thye Goo, Marc Weijie Ong","doi":"10.4274/ejbh.galenos.2022.2022-1-2","DOIUrl":"10.4274/ejbh.galenos.2022.2022-1-2","url":null,"abstract":"<p><strong>Objective: </strong>Patients with breast cancer who have indeterminate extra-mammary lesions, for example in lung, liver or bone, without other metastatic lesions pose a clinical dilemma regarding subsequent management. This study aimed to investigate the prevalence, characteristics and outcomes of such lesions detected on initial staging imaging, and address the clinical significance of these incidental findings.</p><p><strong>Materials and methods: </strong>Medical records of patients with newly diagnosed breast cancer who underwent computed tomography scans and bone scintigraphy between January 1, 2015 and June 30, 2021 were reviewed. Patients with indeterminate extra-mammary lesions on imaging were included. Patients with obvious metastatic disease were excluded. Lesion characteristics, breast cancer staging, duration of follow-up and natural history of disease progression were analysed.</p><p><strong>Results: </strong>The study included 52 patients with indeterminate lesions on pre-operative imaging. The median follow-up duration was 14 (range: 6-41) months. The most common site of occurrence of indeterminate lesions was the lung (60.9%) followed by the liver (26.1%). Forty-six had lesions that remained stable (88.5%), while six (11.5%) had progression to metastatic disease. Out of these six, only two (3.8%) developed metastasis in the same site as the original indeterminate lesion, whereas the remaining four developed metastases in other sites.</p><p><strong>Conclusion: </strong>Patients with breast malignancy found to have indeterminate extra-mammary lesions without obvious distant metastasis on initial staging scans are associated with a small risk of subsequently developing metastatic disease. Although most of these lesions remain quiescent, surveillance imaging is recommended because a small but significant proportion of patients with such lesions eventually harbour actual metastatic disease.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":"18 3","pages":"252-257"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255656/pdf/ejbh-18-252.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40606407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mucormycosis of the Breast in a Patient With Breast Carcinoma After COVID-19 Pneumonia. 1例新冠肺炎后乳腺癌患者的乳腺毛霉病
Pub Date : 2022-07-01 DOI: 10.4274/ejbh.galenos.2022.2022-2-4
S P Somashekhar, Richa Jaiswal, Rohit Kumar, B C Ashok, Susmita Rakshit, Amit Rauthan, H K Karthik, Archa Prasad, Herra Islam, Aaron Fernandes, Elroy Saldahana, K R Ashwin

Mucormycosis is a rare, but potentially fatal, fungal infection which is caused by mucormyctes. These forms of fungi are typically known to infect immuno-compromised individuals but are rare in immunocompetent individuals. Herein, we report the case of a 52 year-old female who was diagnosed with right breast carcinoma in Manipal Hospital, a tertiary cancer care center. The patient was a known diabetic and hypertensive and who had recently recovered from coronavirus disease-2019 (COVID-19) pneumonia. In the due course of management, she developed mucormycosis infection at the operative site in her right breast where she had a radiation therapy-induced wound. This patient was successfully treated with an aggressive regimen of early surgical debridement along with administration of systemic amphotericin B.

毛霉病是一种罕见但可能致命的真菌感染,由毛霉菌引起。这些形式的真菌通常感染免疫功能低下的个体,但在免疫能力强的个体中很少见。在此,我们报告一位52岁的女性在马尼帕尔医院诊断为右乳腺癌,这是一家三级癌症护理中心。该患者是已知的糖尿病和高血压患者,最近从冠状病毒病-2019 (COVID-19)肺炎中康复。在适当的治疗过程中,她在右乳房手术部位出现了毛霉菌病感染,那里有放射治疗引起的伤口。该患者通过积极的早期手术清创方案以及全身性两性霉素B的管理成功治疗。
{"title":"Mucormycosis of the Breast in a Patient With Breast Carcinoma After COVID-19 Pneumonia.","authors":"S P Somashekhar,&nbsp;Richa Jaiswal,&nbsp;Rohit Kumar,&nbsp;B C Ashok,&nbsp;Susmita Rakshit,&nbsp;Amit Rauthan,&nbsp;H K Karthik,&nbsp;Archa Prasad,&nbsp;Herra Islam,&nbsp;Aaron Fernandes,&nbsp;Elroy Saldahana,&nbsp;K R Ashwin","doi":"10.4274/ejbh.galenos.2022.2022-2-4","DOIUrl":"https://doi.org/10.4274/ejbh.galenos.2022.2022-2-4","url":null,"abstract":"<p><p>Mucormycosis is a rare, but potentially fatal, fungal infection which is caused by mucormyctes. These forms of fungi are typically known to infect immuno-compromised individuals but are rare in immunocompetent individuals. Herein, we report the case of a 52 year-old female who was diagnosed with right breast carcinoma in Manipal Hospital, a tertiary cancer care center. The patient was a known diabetic and hypertensive and who had recently recovered from coronavirus disease-2019 (COVID-19) pneumonia. In the due course of management, she developed mucormycosis infection at the operative site in her right breast where she had a radiation therapy-induced wound. This patient was successfully treated with an aggressive regimen of early surgical debridement along with administration of systemic amphotericin B.</p>","PeriodicalId":11885,"journal":{"name":"European journal of breast health","volume":"18 3","pages":"289-291"},"PeriodicalIF":0.0,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9255654/pdf/ejbh-18-289.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40618491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
European journal of breast health
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1